Inhaled Epoprostenol for Pulmonary Hypertension Treatment in Neonates: A 12-Year Experience

Abstract

In these sick newborns, we observed an improvement in PPHN under iPGI₂ without significant adverse effects. To our knowledge, this is the largest neonatal cohort reported to have received iPGI₂ for PPHN.